Replimune Group Inc REPL

$13.42 +0.38 (2.91%)

Valuation

Market cap
1,258,769,000
Revenue TTM
$0
Net income TTM
$-313,940,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.80

Trading

Volume
2,022,700
Avg volume
3,737,054
Day's range
$12.79 – $13.44
Shares out
93,798,000
Stochastic %K
72%
Beta
0.93
Analysts
Strong Sell
Price target
$19.50

Price

Company profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1...

Show more

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 222 9600
Website
https://www.replimune.com
Address
500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, United States

Latest news

Stocktwits

History101 Oct 11, 5:44 PM
$SLS imo GPS approval from the FDA is already in the bag. However, can you imagine the outrage from the entire leukemia community, especially the world reknowned AML doctors who are overseeing the GPS trials, and the frontline docs treating the patients, the doctors who have advocated for (and received) infinite dosing and expanded access, if GPS is not approved?? imo the reaction from the AML community would be 10x the outrage that occurred with the $REPL community when REPL got their unexpected CRLs. Even if the efficacy stats are close, which they won't be (GPS will blow the stats out of the water), imo GPS gets approval based on TOLERABILITY ALONE. A large % of CR2 AML patients choose death rather than the extremely toxic and painful BAT. GLTALs!!
1 replies
themoon123 Oct 9, 10:59 PM
$TENX not enough people talking about this TENX. $SLS $CAPR $REPL
4 replies
VicAge Oct 9, 3:18 PM
$REPL This had a good run. Time to transfer it all over to IOVA that is one is strong in the bio-tech with revenue
0 replies
Perjavs Oct 9, 2:26 PM
$BMEA As I’ve experienced with other biotechs, $REPL , $ANRO and $IBRX last october, we are entering the season, this could go steadily to around $2,50 as new investors see the obvious opportunity, then as the news are published it will jump to $8, afterwards there will be a pullback to $5, and then depending in the market expectations it will go up again slowly or sideways. It’s just a hipotesys based in prior cases.
1 replies
Merlintrader Oct 4, 11:40 PM
Replimune ($REPL): What Does the TUDRIQEV Launch Have to Deliver Against the Hercules Covenant? Explore the company, catalysts and risks in our research hub. https://www.merlintrader.com/replimune-group-stock-hub/
0 replies
DRAM27 Oct 2, 2:56 PM
$REPL we are on track. Take the cheaper shares as a gift. Tutes have loaded. Opportunity of a lifetime. 🚀🚀🚀
0 replies
DRAM27 Oct 2, 2:09 PM
$REPL Hope you guys loaded the boat when this retraced to the $12S. Tutes are loaded... don't bet against them. 🚀🚀🚀
0 replies
Hotresearchsgoldenage Oct 1, 8:28 PM
$REPL great news and crickets
0 replies